ProShares Ultra Health Care ETF

New report shows Eli Lilly and Novo Nordisk dominate GLP-1 drug citations in AI tools

Lilly China Launches "Tuo Hu Chang An" Patient Assistance Program to Support IBD Patients

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Johnson & Johnson Expected to Grow Sales 7% in 2026, Seen as Strong Investment Due to Stable Model and Dividend History

Zacks Raises UnitedHealth's Q1 2027 EPS Estimate to $6.87

Eli Lilly & UNICEF Launch US$50m Partnership Program for Childhood Chronic Diseases

WHO confirms Merck's Ervebo vaccine as candidate for Ebola prevention

Multiple Institutional Investors Disclose Increased Stakes in UnitedHealth Group on May 19, 2026

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Institutional Investor Larson Financial Group LLC Reduces Stake in Eli Lilly

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

InMed Pharmaceuticals

NextNRG

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

Meiwu Tech

QUARTZSEA ACQUISITION CORP ORD USD0.0001 (18/02/2030) (S/R)

CN Energy

Generation Income Properties

MetaVia

SBIO

The US Supreme Court has rejected appeals from major drugmakers against a Medicare program that allows price negotiations for certain drugs, expected to save billions for taxpayers. The decision upholds lower court rulings and follows the 2022 Inflation Reduction Act. Drug companies argue the program violates their rights, but courts have ruled participation in Medicare is voluntary. The first round of negotiations is projected to save $6 billion for the government and reduce costs for seniors.

Yahoo Finance

NOVARTIS AG

Johnson & Johnson

Bristol Myers Squibb

Merck

AstraZeneca

Direxion Pharma & Medical Bull 3X

ALPS Medical Breakthrough

VG Health

Direxion S&P Biotech Bull 3X

iShares US Pharma

AstraZeneca PLC

Bristol-Myers Squibb Company

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

IBBQ

Dana Investment Advisors Inc. reduced its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 46.7% in Q4, owning 48,278 shares valued at $2.60 million. Other institutional investors, including Vanguard and State Street, also adjusted their stakes. Bristol Myers Squibb's stock opened at $57.04, with a market cap of $116.48 billion.

Market Beat

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares Global Healthcare

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

VanEck Biotech ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

State Street

Legal & General Group Plc

Hengrui Pharma

Bank of America

State Street® US Equity Premium Inc ETF

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

HIMS

HIMY

This week, Wall Street saw declines, particularly in technology stocks, while the S&P 500 Health Care Index gained 1.09%. Notable healthcare news includes UnitedHealth's new pharmacy pricing model set for 2027, a $15.2B licensing deal between Bristol Myers Squibb and Hengrui Pharma, and Hims & Hers Health reporting disappointing Q1 results. Additionally, concerns were raised about the potential impact of Trump's drug policy on US biopharma innovation.

businessinsider

Hims & Hers Health

Defiance Leveraged Long +Income HIMS ETF

Invesco S&P 500 Equal Weight Health Care ETF

Defiance Daily Target 2X Long HIMS ETF

iShares US Medical Devices

SPDR S&P Health Equip

iShares US Healthcare Providers

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

MADE

W.W. Grainger VP Laurie Thomson sold 313 shares at $1,231.69 each, totaling $385,518.97, reducing her stake by 43.96%. Post-sale, she holds 399 shares valued at $491,444.31. The transaction was filed with the SEC. The stock recently traded at $1,281.74, with a market cap of $60.51 billion and a P/E ratio of 34.51. Grainger reported $11.65 EPS for the last quarter, exceeding estimates, and announced a dividend increase to $2.49 per share, payable June 1. Institutional investors own 80.70% of the stock.

WW Grainger

Spdr Select Indu

VG Industr

iShares U.S. Manufacturing ETF

Genuine Parts

Fastenal

T. Rowe Price

Barclays

Oppenheimer

W.W. Grainger (NYSE:GWW) VP Laurie Thomson Sells 313 Shares

CURE

Molina Healthcare Inc. (MOH) shares rose 3.45% to $191.58 on Tuesday, ending a three-day losing streak, despite underperforming compared to competitors like Humana Inc. and Centene Corp., which saw gains of 7.69% and 5.23%, respectively. The stock remains 41.53% below its 52-week high of $327.68 reached on May 20. Trading volume was 954,383, significantly below the 50-day average of 1.6 million shares.

MarketWatch Automated

Molina Healthcare

Direxion Healthcare Bull 3X

SPDR S&P Health

Dow Jones Industrial Average

S&P 500

Humana

Centene

Factset Research

Molina Healthcare Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

600276

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

HENGRUI PHARMA

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

01276

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bear 3X

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

Guotai CSI Bio-medicine ETF

Penghua SSE STAR Biology and Medicine ETF

China Merchants CSI Biotechnology Theme ETF

ICBCCS SSE STAR Biology and Medicine ETF

Minsheng Royal CSI Biotechnology Theme ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

BMS and Hengrui forge $15.2bn alliance for early-stage drugs

Forus has raised over $160M to enhance the delivery of modern medicine. The company, formerly known as Tandem, aims to connect doctors, pharmacies, payers, and biopharma through an AI-powered network, streamlining the process of getting new therapies to patients. Backed by prominent investors like Thrive Capital and General Catalyst, Forus addresses the inefficiencies in the current healthcare system, which often delays or prevents patients from receiving necessary treatments. The platform is already in use across all 50 states, supporting millions of patients and expanding rapidly in various medical specialties.

MorningStar

ChinaAMC CSI All Share Health Care Devices ETF

Proshares UltraShort Nasdaq Biotech

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

General Catalyst Global Resilience Merger - Unit

Accel ENT

Bain Capital Specialty Finance

Forus Raises $160M to Build the Foundation for Modern Medicine

Bristol-Myers Squibb (BMY) shares have declined for seven consecutive sessions, dropping 0.9% to $55.64 on Monday. The stock has fallen 3.5% in the previous six sessions and is down 5% over the past month, although it has increased 4% year-to-date. The company recently reported better-than-expected Q1 results.

Bristol-Myers Squibb shares fell for seventh consecutive session

ProShares Ultra Health Care ETF(RXL.US)

Supreme Court rejects big pharma appeals challenging negotiated drug prices in Medicare

Dana Investment Advisors Inc. Has $2.60 Million Holdings in Bristol Myers Squibb Company $BMY

Notable healthcare headlines for the week: UnitedHealth, Bristol Myers Squibb, and Hims & Hers in focus

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

W.W. Grainger (NYSE:GWW) VP Laurie Thomson Sells 313 Shares